Promising results from the Phase 2 study of novel extended-release ketamine tablets (R-107) for Treatment-Resistant Depression accepted for publication by Nature Medicine
AUCKLAND, New Zealand, June 24, 2024 /PRNewswire/ -- Douglas Pharmaceuticals, New Zealand's largest pharmaceutical company, is pleased to announce that…
